ARID1A and bladder transitional cell carcinoma: Next, we selected three urothelial bladder cancer cell lines harboring ARID1A truncating mutations, namely HT1376, JMSU-1, VM-CUB-1 (S1 Fig) and compared their GSK126 treatment response to three bladder cancer cell lines (J82, RT112, SCaBER) without SWI/SNF complex gene alterations.